Institution

# University of Pisa

Education•Pisa, Toscana, Italy•

About: University of Pisa is a education organization based out in Pisa, Toscana, Italy. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 25835 authors who have published 73111 publications receiving 2131507 citations. The organization is also known as: Universitá degli Studi di Pisa & Universita degli Studi di Pisa.

Topics: Population, Large Hadron Collider, Thyroid, Laser, Higgs boson

##### Papers published on a yearly basis

##### Papers

More filters

••

[...]

TL;DR: This biennial Review summarizes much of particle physics, using data from previous editions.

Abstract: This biennial Review summarizes much of particle physics. Using data from previous editions., plus 2778 new measurements from 645 papers, we list, evaluate, and average measured properties of gauge bosons, leptons, quarks, mesons, and baryons. We also summarize searches for hypothetical particles such as Higgs bosons, heavy neutrinos, and supersymmetric particles. All the particle properties and search limits are listed in Summary Tables. We also give numerous tables, figures, formulae, and reviews of topics such as the Standard Model, particle detectors., probability, and statistics. Among the 108 reviews are many that are new or heavily revised including those on CKM quark-mixing matrix, V-ud & V-us, V-cb & V-ub, top quark, muon anomalous magnetic moment, extra dimensions, particle detectors, cosmic background radiation, dark matter, cosmological parameters, and big bang cosmology.

11,048 citations

••

[...]

TL;DR: In this article, a search for the Standard Model Higgs boson in proton-proton collisions with the ATLAS detector at the LHC is presented, which has a significance of 5.9 standard deviations, corresponding to a background fluctuation probability of 1.7×10−9.

Abstract: A search for the Standard Model Higgs boson in proton–proton collisions with the ATLAS detector at the LHC is presented. The datasets used correspond to integrated luminosities of approximately 4.8 fb−1 collected at View the MathML source in 2011 and 5.8 fb−1 at View the MathML source in 2012. Individual searches in the channels H→ZZ(⁎)→4l, H→γγ and H→WW(⁎)→eνμν in the 8 TeV data are combined with previously published results of searches for H→ZZ(⁎), WW(⁎), View the MathML source and τ+τ− in the 7 TeV data and results from improved analyses of the H→ZZ(⁎)→4l and H→γγ channels in the 7 TeV data. Clear evidence for the production of a neutral boson with a measured mass of View the MathML source is presented. This observation, which has a significance of 5.9 standard deviations, corresponding to a background fluctuation probability of 1.7×10−9, is compatible with the production and decay of the Standard Model Higgs boson.

8,774 citations

••

[...]

University of Barcelona

^{1}, University of Pisa^{2}, University of Duisburg-Essen^{3}, Auckland City Hospital^{4}, University of São Paulo^{5}, European University^{6}, Icahn School of Medicine at Mount Sinai^{7}, Goethe University Frankfurt^{8}, University of Bologna^{9}, Hannover Medical School^{10}, University of Mainz^{11}, Aix-Marseille University^{12}, Université catholique de Louvain^{13}, University of Düsseldorf^{14}, Bayer^{15}, Bayer Corporation^{16}TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.

Abstract: Background No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. Methods In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. Results At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P<0.001). There was no significant difference between the two groups in the median time to symptomatic progression (4.1 months vs. 4.9 months, respectively, P=0.77). The median time to radiologic progression was 5.5 months in the sorafenib group and 2.8 months in the placebo group (P<0.001). Seven patients in the sorafenib group (2%) and two patients in the placebo group (1%) had a partial response; no patients had a complete response. Diarrhea, weight loss, hand-foot skin reaction, and hypophosphatemia were more frequent in the sorafenib group. Conclusions In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.

8,412 citations

••

[...]

TL;DR: In this paper, results from searches for the standard model Higgs boson in proton-proton collisions at 7 and 8 TeV in the CMS experiment at the LHC, using data samples corresponding to integrated luminosities of up to 5.8 standard deviations.

Abstract: Results are presented from searches for the standard model Higgs boson in proton-proton collisions at sqrt(s)=7 and 8 TeV in the CMS experiment at the LHC, using data samples corresponding to integrated luminosities of up to 5.1 inverse femtobarns at 7 TeV and 5.3 inverse femtobarns at 8 TeV. The search is performed in five decay modes: gamma gamma, ZZ, WW, tau tau, and b b-bar. An excess of events is observed above the expected background, a local significance of 5.0 standard deviations, at a mass near 125 GeV, signalling the production of a new particle. The expected significance for a standard model Higgs boson of that mass is 5.8 standard deviations. The excess is most significant in the two decay modes with the best mass resolution, gamma gamma and ZZ; a fit to these signals gives a mass of 125.3 +/- 0.4 (stat.) +/- 0.5 (syst.) GeV. The decay to two photons indicates that the new particle is a boson with spin different from one.

8,357 citations

••

[...]

TL;DR: In this article, a method is presented which utilizes the calculation of the molecular electrostatic potential or the electric field at a discrete number of preselected points to evaluate the environmental effects of a solvent on the properties of a molecular system.

Abstract: A method is presented which utilizes the calculation of the molecular electrostatic potential or the electric field at a discrete number of preselected points to evaluate the environmental effects of a solvent on the properties of a molecular system. No limitations are imposed on the composition and dimension of the solute, on the goodness of the corresponding wavefunction, or on the shape of the cavity in the dielectric. Several levels of approximation, which evidence the effect of self-polarization of the system of surface charges, the influence of the tails of the solute charge distribution going beyond the limits of the cavity, and the effect of the polarization of the solute, are examined and discussed.

6,963 citations

##### Authors

Showing all 25835 results

Name | H-index | Papers | Citations |
---|---|---|---|

Hyun-Chul Kim | 176 | 4076 | 183227 |

Ralph A. DeFronzo | 160 | 759 | 132993 |

Yongsun Kim | 156 | 2588 | 145619 |

M. Razzano | 155 | 515 | 106357 |

Lorenzo Bianchini | 152 | 1516 | 106970 |

Andrew White | 149 | 1494 | 113874 |

Subir Sarkar | 149 | 1542 | 144614 |

Paul Jackson | 141 | 1372 | 93464 |

G. Calderini | 139 | 1734 | 102408 |

Guido Tonelli | 138 | 1458 | 97248 |

Brad Abbott | 137 | 1566 | 98604 |

Christoph Paus | 137 | 1585 | 100801 |

Georgios B. Giannakis | 137 | 1321 | 73517 |

G. Marchiori | 137 | 1590 | 94277 |

Andrea Giammanco | 135 | 1362 | 98093 |